Dr Lore Decoster speaks to ecancer at the SIOG 2019 meeting in Geneva about the use of immunotherapy and targeted agents to treat elderly lung cancer patients

She explains that clinicians aren't certain of how the immune system reacts to immunotherapy in older patients and, although some retrospective studies have indicated no differences, one study suggested that patients aged over 80 benefit less.

Dr Decoster adds that while some targeted agents are useful because the targets are more frequent in older patients, the toxicities need to be observed carefully.

This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.